S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway

Neogen (NEOG) Competitors

$17.19
0.00 (0.00%)
(As of 03/1/2024 ET)

NEOG vs. QDEL, NTLA, LNTH, CLDX, MYGN, RYZB, HAE, PRGO, NVST, and BEAM

Should you be buying Neogen stock or one of its competitors? The main competitors of Neogen include QuidelOrtho (QDEL), Intellia Therapeutics (NTLA), Lantheus (LNTH), Celldex Therapeutics (CLDX), Myriad Genetics (MYGN), RayzeBio (RYZB), Haemonetics (HAE), Perrigo (PRGO), Envista (NVST), and Beam Therapeutics (BEAM). These companies are all part of the "medical" sector.

Neogen vs.

QuidelOrtho (NASDAQ:QDEL) and Neogen (NASDAQ:NEOG) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings, community ranking and analyst recommendations.

QuidelOrtho currently has a consensus target price of $66.50, suggesting a potential upside of 46.06%. Neogen has a consensus target price of $23.50, suggesting a potential upside of 36.71%. Given Neogen's higher probable upside, research analysts plainly believe QuidelOrtho is more favorable than Neogen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
QuidelOrtho
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17
Neogen
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

QuidelOrtho received 109 more outperform votes than Neogen when rated by MarketBeat users. Likewise, 67.33% of users gave QuidelOrtho an outperform vote while only 57.29% of users gave Neogen an outperform vote.

CompanyUnderperformOutperform
QuidelOrthoOutperform Votes
439
67.33%
Underperform Votes
213
32.67%
NeogenOutperform Votes
330
57.29%
Underperform Votes
246
42.71%

93.9% of QuidelOrtho shares are held by institutional investors. Comparatively, 96.7% of Neogen shares are held by institutional investors. 2.7% of QuidelOrtho shares are held by insiders. Comparatively, 0.7% of Neogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, QuidelOrtho had 6 more articles in the media than Neogen. MarketBeat recorded 9 mentions for QuidelOrtho and 3 mentions for Neogen. QuidelOrtho's average media sentiment score of 1.21 beat Neogen's score of 0.60 indicating that Neogen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
QuidelOrtho
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Neogen
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Neogen has a net margin of 1.28% compared to Neogen's net margin of -0.34%. Neogen's return on equity of 5.54% beat QuidelOrtho's return on equity.

Company Net Margins Return on Equity Return on Assets
QuidelOrtho-0.34% 5.54% 3.21%
Neogen 1.28%3.35%2.31%

QuidelOrtho has higher revenue and earnings than Neogen. QuidelOrtho is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
QuidelOrtho$3.00B1.01-$10.10M-$0.16-284.56
Neogen$822.45M4.53-$22.87M$0.06286.55

QuidelOrtho has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Comparatively, Neogen has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500.

Summary

QuidelOrtho beats Neogen on 10 of the 18 factors compared between the two stocks.


Get Neogen News Delivered to You Automatically

Sign up to receive the latest news and ratings for NEOG and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEOG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NEOG vs. The Competition

MetricNeogenDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$3.72B$3.21B$5.21B$7.62B
Dividend YieldN/A0.83%2.82%3.87%
P/E Ratio286.5551.11257.3718.81
Price / Sales4.5352.503,092.04110.79
Price / Cash18.895,856.7099.8655.35
Price / Book1.194.204.534.54
Net Income-$22.87M$30.34M$114.95M$211.55M
7 Day Performance1.36%1.61%5.72%3.36%
1 Month Performance9.98%1.18%12.81%6.70%
1 Year Performance-9.91%-32.49%12.92%7.44%

Neogen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
QDEL
QuidelOrtho
4.8563 of 5 stars
$46.80
+2.0%
$66.50
+42.1%
-48.4%$3.13B$3.00B-292.507,000
NTLA
Intellia Therapeutics
4.1152 of 5 stars
$31.02
+12.1%
$66.93
+115.8%
-25.8%$2.98B$36.28M-5.73598Analyst Revision
High Trading Volume
LNTH
Lantheus
4.846 of 5 stars
$68.26
+0.2%
$104.14
+52.6%
-11.9%$4.68B$1.30B14.71698Positive News
CLDX
Celldex Therapeutics
0.4345 of 5 stars
$51.04
+5.8%
$62.25
+22.0%
+11.8%$2.41B$2.36M-19.33148Analyst Report
Analyst Revision
News Coverage
High Trading Volume
MYGN
Myriad Genetics
3.3901 of 5 stars
$23.50
+2.5%
$23.75
+1.1%
-3.1%$1.93B$678.40M-6.992,600Earnings Report
RYZB
RayzeBio
0.4681 of 5 stars
$62.49
flat
$31.33
-49.9%
N/A$3.74BN/A0.0088Upcoming Earnings
HAE
Haemonetics
4.6142 of 5 stars
$74.28
+1.5%
$104.67
+40.9%
-3.6%$3.77B$1.17B30.203,034Analyst Downgrade
Short Interest ↑
Analyst Revision
PRGO
Perrigo
4.9813 of 5 stars
$27.30
-15.1%
$44.25
+62.1%
-31.2%$3.70B$4.65B546.118,900Earnings Report
Dividend Increase
Analyst Downgrade
Insider Buying
News Coverage
High Trading Volume
NVST
Envista
4.8011 of 5 stars
$21.44
-2.2%
$29.60
+38.1%
-46.4%$3.68B$2.57B-35.1512,800Short Interest ↓
Analyst Revision
BEAM
Beam Therapeutics
0.9434 of 5 stars
$45.07
+25.9%
$43.92
-2.6%
+2.7%$3.67B$81.55M-10.81439Earnings Report
Analyst Report
Analyst Revision
News Coverage
High Trading Volume

Related Companies and Tools

This page (NASDAQ:NEOG) was last updated on 3/3/2024 by MarketBeat.com Staff